Reversal of Myelofibrosis in a Patient with Low Risk Myelodysplastic Syndrome on Revlimid Therapy.

Overview of attention for article published in Blood, November 2005

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

patent: 3 patents

So far, Altmetric has seen 3 patents that reference this research output.

Immunomodulatory compound for the treatment of myeloproliferative diseases

Grant EP-1567157-B1

European Patent Office

Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-…

Grant US-8034831-B2

United States of America

Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the…

Grant US-7563810-B2

United States of America

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity.